SANOFI-AVENTIS Form 6-K January 06, 2005 UNITED STATES							
SECURITIES AND EXCHANGE COMMISSION							
Washington, D.C. 20549							
FORM 6-K							
REPORT OF FOREIGN PRIVATE ISSUER							
PURSUANT TO RULE 13a-16 OR 15d-16							
UNDER THE SECURITIES EXCHANGE ACT OF 1934							
For the month of January 2005							
Commission File Number: 001-31368							
SANOFI-AVENTIS							
(Translation of registrant s name into English)							
174, avenue de France, 75013 Paris, FRANCE							
(Address of principal executive offices)							
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.							
Form 20-F [X] Form 40-F []							
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):							
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):							

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Ye	s [] No[X]
If	Yes	marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82

On January 6, 2005, Sanofi-Aventis issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

Exhibit List

Exhibit No. Description

Exhibit 99.1 Press Release, dated January 6, 2005, announcing an update in the patent litigation schedule in the United States for

Plavix®.

GN		

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: January 6, 2005

SANOFI-AVENTIS

By: /s/ Jean-Claude Leroy

Name: Jean-Claude Leroy
Title: Senior Vice President &
Chief Financial Officer

Exhibit Index

Exhibit No. Description

Exhibit 99.1 Press Release, dated January 6, 2005, announcing an update in the patent litigation schedule in the United States for

Plavix®.